Search

Zhichang Xu Phones & Addresses

  • Kalamazoo, MI
  • Danville, CA
  • San Francisco, CA
  • Fort Dodge, IA
  • College Station, TX
  • 7873 Shepherds Glen Ct, Kalamazoo, MI 49009 (269) 870-7089

Publications

Us Patents

Mycoplasma Hyopneumoniae Bacterin Vaccine

View page
US Patent:
7666439, Feb 23, 2010
Filed:
Aug 21, 2006
Appl. No.:
11/507231
Inventors:
Wumin Li - Fort Dodge IA,
Zhichang Xu - Fort Dodge IA,
Assignee:
Wyeth LLC - Madison NJ
International Classification:
A61K 39/02
A61K 39/116
A61K 39/38
A01N 63/00
A01N 65/00
US Classification:
4242641, 4241841, 4242031, 4242341, 424 934, 424 931, 424825
Abstract:
The invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated bacterin and an adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Mycoplasma Hyopneumoniae Bacterin Vaccine

View page
US Patent:
2002013, Sep 19, 2002
Filed:
Jan 8, 2002
Appl. No.:
10/039383
Inventors:
Wumin Li - Fort Dodge IA,
Zhichang Xu - Fort Dodge IA,
Assignee:
American Home Products Corporatio - Madison NJ
International Classification:
A61K039/116
A61K039/02
US Classification:
424/203100, 424/264100
Abstract:
The invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated bacterin and an adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably Carbopol, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Mycoplasma Hyopneumoniae Bacterin Vaccine

View page
US Patent:
2003001, Jan 23, 2003
Filed:
May 17, 2002
Appl. No.:
10/150597
Inventors:
Wumin Li - Fort Dodge IA,
Zhichang Xu - Fort Dodge IA,
Assignee:
Wyeth - Madison NJ
International Classification:
A61K039/295
A61K039/04
US Classification:
424/201100, 424/248100
Abstract:
The invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated bacterin and an adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably Carbopol, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another emodiment, the invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

Mycoplasma Hyopneumoniae Avirulent Adjuvanted Live Vaccine

View page
US Patent:
2009011, May 7, 2009
Filed:
Nov 5, 2008
Appl. No.:
12/265274
Inventors:
Zhichang Xu - Fort Dodge IA,
Wumin Li - Fort Dodge IA,
Nicole Rae Gibson - Humboldt IA,
Assignee:
Wyeth - Madison NJ
International Classification:
A61K 39/02
US Classification:
4242011, 4242641, 4242031
Abstract:
Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating infection. Administration to an animal of one or two doses of an adjuvanted live avirulent composition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain of thereby reducing the severity of and/or preventing disease caused by one or more virulent strain of . Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and/or virus and/or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulent and compositions, comprising Porcine Circovirus Type 1-Type 2 chimera modified live vaccine (cPCV1-2) in further combination with an adjuvanted live avirulent

Mycoplasma Hyopneumoniae Bacterin Vaccine

View page
US Patent:
2012021, Aug 23, 2012
Filed:
Apr 27, 2012
Appl. No.:
13/458541
Inventors:
Wumin Li - Fort Dodge IA,
Zhichang Xu - Fort Dodge IA,
International Classification:
A61K 39/39
A61P 31/04
US Classification:
4242031, 4242641
Abstract:
The invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated bacterin and an adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Mycoplasma Hyopneumoniae Bacterin Vaccine

View page
US Patent:
2010011, May 13, 2010
Filed:
Jan 22, 2010
Appl. No.:
12/692275
Inventors:
Wumin Li - Fort Dodge IA,
Zhichang Xu - Fort Dodge IA,
Assignee:
Wyeth LLC - Madison NJ
International Classification:
A61K 31/765
A61P 31/04
A61P 37/04
US Classification:
424 7818
Abstract:
The invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated bacterin and an adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Mycoplasma Hyopneumoniae Bacterin Vaccine

View page
US Patent:
2010006, Mar 11, 2010
Filed:
Nov 16, 2009
Appl. No.:
12/618842
Inventors:
Wumin Li - Fort Dodge IA,
Zhichang Xu - Fort Dodge IA,
Assignee:
Wyeth - Madison NJ
International Classification:
A61K 39/116
A61K 39/02
A61P 31/04
US Classification:
4242031, 4242641
Abstract:
The invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated bacterin and an adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably Carbopol, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

Mycoplasma Hyopneumoniae Bacterin Vaccine

View page
US Patent:
2007013, Jun 14, 2007
Filed:
Jan 11, 2007
Appl. No.:
11/652306
Inventors:
Wumin Li - Fort Dodge IA,
Zhichang Xu - Fort Dodge IA,
International Classification:
A61K 39/295
US Classification:
424202100
Abstract:
The invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated bacterin and an adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably Carbopol, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improved bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from infection after a single administration, and elicit an immune response specific to bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.
Zhichang Xu from Kalamazoo, MI Get Report